Enliven Therapeutics Inc., a clinical-stage biopharmaceutical company, has released its financial results for the second quarter of 2025. The company reported a net loss of $25.3 million for the quarter, an increase from the $20.0 million net loss reported in the same period of 2024. Research and development expenses for the quarter rose to $21.5 million, up from $18.8 million in the prior year's second quarter. General and administrative expenses also increased to $7.1 million from $5.8 million in the second quarter of 2024. Enliven highlighted positive data from the Phase 1 clinical trial of ELVN-001 in chronic myeloid leukemia $(CML.UK)$, with a cumulative major molecular response $(MMR.AU)$ rate of 47% and 32% of patients achieving MMR by 24 weeks. The company reported that ELVN-001 demonstrated a favorable safety and tolerability profile across all dose levels. The company maintains a strong balance sheet with $491 million in cash, cash equivalents, and marketable securities, which is expected to sustain operations into the first half of 2029. Looking ahead, Enliven plans to initiate its first Phase 3 pivotal trial of ELVN-001 in 2026, building on the positive clinical data reported. The company also strengthened its financial position through a recent public offering, generating approximately $230 million in gross proceeds.